American Shared Hospital Services (AMS) Earnings Call Transcript & Summary
November 10, 2021
Earnings Call Speaker Segments
Stephanie Prince
executiveThank you, Carrie, and I appreciate all of you being here with us today. Ahead of handing things over to management, I'd like to offer a few comments about forward-looking statements. Please be aware that any number of things we might say during this conference call regarding future expectations, plans and prospects for the company count as forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from what those forward-looking statements indicate, owing to a range of important factors, among them the ones covered in the company's filings with the SEC. Those include the annual report on Form 10-K for the year ended December 31, 2020, the quarterly report on Form 10-Q for the quarters ended March 31 and June 30, 2021, and the definitive proxy statement for the Annual Meeting of Shareholders that was held on June 25, 2021. No obligation is assumed by the company to update the information contained in this conference call. At this point I'd like to hand the call over to Ray Stachowiak, CEO of AMS. Ray? Ray?
Ray Stachowiak
executiveThanks, Stephanie. Hello, everyone, and good afternoon. We appreciate you being with us for the earnings conference call covering our third quarter of 2021. I'll start things off with a few opening comments, and then we'll change things up a little from how we normally do it, with Alexis Wallace, who serves as our Chief Accounting Officer, giving a financial review. Then Craig Tagawa, our President, COO and CFO, will walk through an operational review of results. Once the prepared remarks are done, Craig, Alexis, Ernie Bates — our Senior Vice President, Sales and Business Development and International Operations — and I will take your questions. During the third quarter, COVID-19 kept affecting AMS, and we also dealt with unplanned downtime of our proton beam system. Total revenue fell 12% compared with the same period a year earlier. Costs kept coming down thanks to the favorable effect of our year-end balance sheet restructuring along with the debt refinancing we finished in April. Operating income came in at $186,000, marking our third quarter in a row of positive results. Craig and Alexis will share the specifics shortly. Now that our financial house is in order and we have a broader set of radiation therapy equipment offerings available, we've shifted focus toward growing our addressable market. This quarter, we announced a business development services agreement that will extend our sales and marketing reach to every federal facility across the United States. That covers all Veteran Affairs, VA hospitals and Department of Defense hospitals, among them numerous of the most highly regarded facilities in our country. We still have considerable resources available to put toward future opportunities; we hold more than $7 million in cash along with a $7 million line of credit; we're prepared to deploy these resources, and I'm eager to talk about our progress in the months ahead. I'll hand the call over now to Alexis for the third quarter financial review. Alexis?
Alexis Wallace
executiveThanks, Ray, and good afternoon, everyone. Before I move into my prepared remarks, I'd like to direct your attention to the earnings press release for our third quarter, which was issued earlier today. If you need a copy, it's available on our website, ashs.com, under the Investors tab in the Press Releases section. Now let's turn to our third quarter results. During the 3 months that ended September 30, 2021, revenue decreased 12.2%, coming in at $4.099 million, compared with $4.670 million in revenue for the third quarter of 2020. For the proton therapy system the company has installed at Orlando Health in Florida, third quarter revenue declined 23.4%, totaling $1.293 million, against revenue of $1.687 million for the third quarter of 2020. During Q3, we recorded 973 proton therapy fractions overall, which represents a 40.4% decrease from the 1,632 fractions seen in the same quarter of 2020. For our Gamma Knife business, third-quarter 2021 revenue was $2.806 million, a 5.9% drop versus the $2.983 million posted in Q3 2020. Procedures involving Gamma Knife decreased 10.9%, totaling 336 in the third quarter of 2021, compared with 377 during the equivalent period a year earlier. In Q3 2021, gross margin increased 28.9% to $1.467 million, equal to 35.8% of revenue, up from a gross margin of $1.138 million, or 24.4% of revenue, in the third quarter of 2020. For the three-month period, selling and administrative costs came in at $1.119 million, down 1.4% from $1.135 million in the same period a year earlier, driven by reduced legal, accounting, and tax fees. Interest expense dropped 36.2%, landing at $162,000 versus $254,000 in the comparable period of the prior year. The third quarter of 2021 produced operating income of $186,000, compared with an operating loss of $251,000 in the third quarter of 2020 — a favorable swing of $437,000. Net income for the third quarter totaled $33,000, or $0.01 per diluted share, versus a net loss of $209,000, or $0.03 per diluted share, in the third quarter of 2020. For Q3 2021, the fully diluted weighted average count of common shares outstanding came to 6.123 million, while in the same period of 2020 it stood at 6.049 million. On a non-GAAP basis, adjusted EBITDA reached $1.562 million during the third quarter of 2021, down from $1.979 million in the comparable 2020 quarter. As of September 30, 2021, the company held $7.168 million in cash, cash equivalents and restricted cash, up from $4.325 million on December 31, 2020. Shareholders' equity totaled $23.953 million at September 30, 2021, equal to $4.08 for each outstanding share. That's versus $23.650 million, or $4.08 per outstanding share, in shareholders' equity as of December 31, 2020. Now I'll hand things over to Craig, who will walk us through the operational review for the third quarter. Craig?
Craig Tagawa
executiveThanks, Alexis, and good afternoon to all of you. As Alexis said, our total revenue for the third quarter came to $4.1 million, which represents a 12.2% drop compared with last year. That decrease is a reflection of the sluggish rebound from COVID made worse by the Delta variant over the summer, plus unanticipated downtime affecting our PBRT system. Revenue in the third quarter from the proton therapy system located at Orlando Health in Florida totaled $1.3 million, down 23.4% versus the prior year. Higher average reimbursement for each fraction helped offset the lower volumes. Overall proton therapy fractions fell by slightly more than 40%, landing at 973; the main reasons were the ongoing effects of COVID-19, since treatment volumes keep trailing where they stood before the pandemic, along with the downtime needed to fix certain components of the systems. Gamma Knife revenue dropped 5.9% to $2.8 million. That decline stemmed from fewer procedures, which was partly offset by a rise in average reimbursement. The higher average reimbursement came about because a contract expired in the fourth quarter that had been reimbursed at a lower rate, together with an increase in the average rate at the company's retail sites. Gamma Knife procedures for the third quarter fell by 10.9% to 336, chiefly because of the expiration of 1 contract in the fourth quarter of 2020 and another in the first quarter of 2021, both of them high-volume customers; on a same-store basis, Gamma Knife revenues — Gamma Knife volumes for the same centers in operation rose 11.6% compared with the Gamma Knife volumes at those same centers during the equivalent period a year earlier. Gross margin rose 29% to $1.5 million, up from $1.1 million in the 2020 third quarter. That gain was mainly attributable to a 32.7% reduction in depreciation and amortization, which resulted from the year-end balance sheet restructuring, as well as the 1 contract expiration in second — fourth quarter 2020 and 1 in first quarter 2021. Other direct operating costs fell 26.4%, largely because of the 1 contract expiration in the first quarter of 2021 and a decline in operating costs at the company's existing retail sites. The gross margin percentage stood at 35.8% this quarter, versus 24.4% in the third quarter a year ago, and was basically flat against the second quarter 2021 figure of 35.9%. Selling and administrative costs went down by 1.4% to $1.1 million, driven by lower legal, accounting and tax fees. Interest expense fell 36.2% to $162,000, compared with $254,000 during the same period last year. This reduction mirrors the benefit we gained from the April refinancing of most of our existing debt and finance lease portfolio at an effective interest rate below what the company's historic portfolio rate had been. Operating income for the quarter was $186,000, versus an operating loss of $251,000 in the third quarter of 2020. That's a favorable swing of $437,000, and it reflects the lower direct operating costs and interest expense. Like Ray said, operating income stayed in the black for a third quarter in a row; because of the restructuring, the refinancing and other cost programs, our view is that this pattern can hold. We just got our 2022 reimbursement rates from the Centers for Medicare and Medicaid. For a Medicare Gamma Knife treatment, the delivery code reimbursement rate has been fixed at roughly $7,943, which is 2.2% above the 2021 figure of $7,773. For PBRT delivery, the approximate CMS reimbursement rate for a simple treatment without compensation will be $554 in 2022 versus $543 in 2021, and $1,321 versus $1,298 in 2021 for simple with compensation, intermediate and complex treatments, respectively. During the fourth quarter, we anticipate finishing a Cobalt-60 reload and software upgrades for a customer who extended their contract to 5 years not long ago. Another contract extension was signed by us in the third quarter too. The upgrade at Gamma Knife Center Ecuador is now slated for completion in mid-2022; it will rank among the few Gamma Knife units across all of South America; talks keep going on with both existing and potential clients regarding expanded radiation therapy system products. That brings the formal portion of our presentation to a close. Carrie, at this point we want to hand the call back to you for questions.
Ray Stachowiak
executiveAlright Carrie, Ray Stachowiak here. I want to express appreciation to each of you for being with us on this call today; given the broader marketing initiative we've put in place along with additional efforts currently being worked out, we have strong confidence in what lies ahead for AMS. Should anything come up, reach out — get in touch with us straight away if questions arise prior to our year-end conference call happening in mid-March. Take care of yourselves and remain safe. That's all.
Operator
operatorThat wraps up our call. We appreciate everyone joining us for today's presentation. At this point, you're free to hang up your lines. Have a wonderful day.
For developers and AI pipelines
Programmatic access to American Shared Hospital Services earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in American Shared Hospital Services or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.